Nektar Therapeutics buy michaelkr
Start price
28.11.21
/
50%
€10.01
Target price
28.11.22
-
Performance (%)
9.40%
End price
12.12.21
€10.95
Summary
This prediction ended on 12.12.21 with a price of €10.95. With a performance of 9.40%, the BUY prediction by michaelkr for Nektar Therapeutics closed with a slight gain. michaelkr has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Nektar Therapeutics | 0.517% | 0.517% | 170.270% |
iShares Core DAX® | -0.116% | 1.953% | 14.155% |
iShares Nasdaq 100 | -2.733% | -1.273% | 31.828% |
iShares Nikkei 225® | -1.721% | 3.263% | 12.922% |
iShares S&P 500 | -1.527% | 0.194% | 27.117% |
Comments by michaelkr for this prediction
In the thread Nektar Therapeutics diskutieren
Buy Nektar Therapeutics
In the thread Trading Nektar Therapeutics
Buy beendet